Viking Therapeutics is expected to report zero revenue and a consensus loss of $1.21 per share, while its current price of $35.83 sits well below the average analyst target of $93.60. Investors are primarily focused on the clinical progress of VK2735, the company's lead dual GLP-1/GIP receptor agonist for obesity.
The projected widening of losses year-over-year is driven by a significant surge in research and development costs as the Phase 3 VANQUISH trials accelerate. Shareholders are also looking for updates on the subcutaneous maintenance dosing study results and the definitive timeline for the initiation of the late-stage oral VK2735 program.